Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy.

Literature DB >> 28153085

The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy.

Felipe Bedoya¹, Matthew J Frigault¹, Marcela V Maus².

Abstract

Autologous T cells modified to recognize novel antigen targets are a novel form of therapy for cancer. We review the various potential forms of observed and hypothetical toxicities associated with genetically modified T cells. Despite the focus on toxicities in this review, re-directed T cells represent a powerful and highly effective form of anti-cancer therapy; we remain optimistic that the common toxicities will become routinely manageable and that some theoretical toxicity will be exceedingly rare, if ever observed.

Entities: Disease

Keywords: CAR T cells; adoptive therapy; toxicity

Mesh：

Year: 2017 PMID： 28153085 PMCID： PMC5368422 DOI： 10.1016/j.ymthe.2016.11.011

Source DB: PubMed Journal: Mol Ther ISSN： 1525-0016 Impact factor: 11.454

55 in total

1. Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.

Authors: Carlos A Ramos; Barbara Savoldo; Vicky Torrano; Brandon Ballard; Huimin Zhang; Olga Dakhova; Enli Liu; George Carrum; Rammurti T Kamble; Adrian P Gee; Zhuyong Mei; Meng-Fen Wu; Hao Liu; Bambi Grilley; Cliona M Rooney; Malcolm K Brenner; Helen E Heslop; Gianpietro Dotti
Journal: J Clin Invest Date: 2016-06-06 Impact factor: 14.808

2. Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors: Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal: N Engl J Med Date: 2014-10-16 Impact factor: 91.245

3. Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.

Authors: Chun-Meng Wang; Zhi-Qiang Wu; Yao Wang; Ye-Lei Guo; Han-Ren Dai; Xiao-Hui Wang; Xiang Li; Ya-Jing Zhang; Wen-Ying Zhang; Mei-Xia Chen; Yan Zhang; Kai-Chao Feng; Yang Liu; Su-Xia Li; Qing-Ming Yang; Wei-Dong Han
Journal: Clin Cancer Res Date: 2016-08-31 Impact factor: 12.531

4. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.

Authors: Cor H J Lamers; Ralph Willemsen; Pascal van Elzakker; Sabine van Steenbergen-Langeveld; Marieke Broertjes; Jeannette Oosterwijk-Wakka; Egbert Oosterwijk; Stefan Sleijfer; Reno Debets; Jan W Gratama
Journal: Blood Date: 2010-10-01 Impact factor: 22.113

5. Regulation of macrophage function by interferon-gamma. Somatic cell genetic approaches in murine macrophage cell lines to mechanisms of growth inhibition, the oxidative burst, and expression of the chronic granulomatous disease gene.

Authors: M Goldberg; L S Belkowski; B R Bloom
Journal: J Clin Invest Date: 1990-02 Impact factor: 14.808

6. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors: Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal: Sci Transl Med Date: 2014-02-19 Impact factor: 17.956

7. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

Authors: Cor Hj Lamers; Stefan Sleijfer; Sabine van Steenbergen; Pascal van Elzakker; Brigitte van Krimpen; Corrien Groot; Arnold Vulto; Michael den Bakker; Egbert Oosterwijk; Reno Debets; Jan W Gratama
Journal: Mol Ther Date: 2013-02-19 Impact factor: 11.454

8. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

Authors: Gregory L Beatty; Andrew R Haas; Marcela V Maus; Drew A Torigian; Michael C Soulen; Gabriela Plesa; Anne Chew; Yangbing Zhao; Bruce L Levine; Steven M Albelda; Michael Kalos; Carl H June
Journal: Cancer Immunol Res Date: 2014-02 Impact factor: 11.151

9. Current concepts in the diagnosis and management of cytokine release syndrome.

Authors: Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal: Blood Date: 2014-05-29 Impact factor: 22.113

10. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.

Authors: Adrienne H Long; Waleed M Haso; Jack F Shern; Kelsey M Wanhainen; Meera Murgai; Maria Ingaramo; Jillian P Smith; Alec J Walker; M Eric Kohler; Vikas R Venkateshwara; Rosandra N Kaplan; George H Patterson; Terry J Fry; Rimas J Orentas; Crystal L Mackall
Journal: Nat Med Date: 2015-05-04 Impact factor: 53.440

14 in total

Review 1. Reprogramming cellular functions with engineered membrane proteins.

Authors: Caroline Arber; Melvin Young; Patrick Barth
Journal: Curr Opin Biotechnol Date: 2017-07-11 Impact factor: 9.740

2. Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial.

Authors: Stephen J Schuster; Richard T Maziarz; Elisha S Rusch; Junlong Li; James E Signorovitch; Vadim V Romanov; Frederick L Locke; David G Maloney
Journal: Blood Adv Date: 2020-04-14

3. CAR-T Cells: A Systematic Review and Mixed Methods Analysis of the Clinical Trial Landscape.

Authors: David Pettitt; Zeeshaan Arshad; James Smith; Tijana Stanic; Georg Holländer; David Brindley
Journal: Mol Ther Date: 2017-11-02 Impact factor: 11.454

4. Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide.

Authors: Max Jan; Irene Scarfò; Rebecca C Larson; Amanda Walker; Andrea Schmidts; Andrew A Guirguis; Jessica A Gasser; Mikołaj Słabicki; Amanda A Bouffard; Ana P Castano; Michael C Kann; Maria L Cabral; Alexander Tepper; Daniel E Grinshpun; Adam S Sperling; Taeyoon Kyung; Quinlan L Sievers; Michael E Birnbaum; Marcela V Maus; Benjamin L Ebert
Journal: Sci Transl Med Date: 2021-01-06 Impact factor: 17.956

5. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.

Authors: Nina Shah; Jack Aiello; David E Avigan; Jesus G Berdeja; Ivan M Borrello; Ajai Chari; Adam D Cohen; Karthik Ganapathi; Lissa Gray; Damian Green; Amrita Krishnan; Yi Lin; Elisabet Manasanch; Nikhil C Munshi; Ajay K Nooka; Aaron P Rapoport; Eric L Smith; Ravi Vij; Madhav Dhodapkar
Journal: J Immunother Cancer Date: 2020-07 Impact factor: 13.751

Review 6. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.

Authors: Pavlina Chuntova; Kira M Downey; Bindu Hegde; Neil D Almeida; Hideho Okada
Journal: Front Immunol Date: 2019-01-22 Impact factor: 7.561

7. Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell.

Authors: Yanran He; Karin Schreiber; Steven P Wolf; Frank Wen; Catharina Steentoft; Jonathan Zerweck; Madeline Steiner; Preeti Sharma; H Michael Shepard; Avery Posey; Carl H June; Ulla Mandel; Henrik Clausen; Matthias Leisegang; Stephen C Meredith; David M Kranz; Hans Schreiber
Journal: JCI Insight Date: 2019-11-01